Cargando…
Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients
To analyze the relationship between olanzapine blood concentration and clinical efficacy in schizophrenia patients, which has been expected to provide a scientific reference basis for improving the treatment effect of olanzapine in schizophrenia patients. Four hundred eighty-six psychiatric inpatien...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997772/ https://www.ncbi.nlm.nih.gov/pubmed/36897697 http://dx.doi.org/10.1097/MD.0000000000032912 |
_version_ | 1784903324315680768 |
---|---|
author | Yuan, Mei Yuan, Bo-Zhi Wu, Jiang |
author_facet | Yuan, Mei Yuan, Bo-Zhi Wu, Jiang |
author_sort | Yuan, Mei |
collection | PubMed |
description | To analyze the relationship between olanzapine blood concentration and clinical efficacy in schizophrenia patients, which has been expected to provide a scientific reference basis for improving the treatment effect of olanzapine in schizophrenia patients. Four hundred eighty-six psychiatric inpatients were randomly selected from October 31, 2019, to October 31, 2020, and all enrolled patients were given olanzapine treatment, and the treatment effect of schizophrenia patients was assessed according to the Positive and Negative Symptom Scale subtraction rate, and divided into treatment effective and ineffective groups at 1, 2, and 3 weeks of treatment, respectively. The olanzapine blood concentration in the body was monitored at 1, 2, and 3 weeks of treatment, and the relationship between olanzapine blood concentration and treatment effect at different time points was analyzed. Patients in the ineffective group had lower olanzapine blood concentrations than the effective group in treatment 1, 2, and 3 weeks and lower Positive and Negative Symptom Scale score reduction rates than the effective group (P < .05); the differences in other baseline information between the groups were not statistically significant (P > .05). Logistic regression analysis showed that olanzapine blood concentration at different times of treatment was related to the treatment effect (odds ratio > 1, P < .05); the results of the bivariate Spearman linear correlation test showed that olanzapine blood concentration at different times of treatment was positively related to the treatment effect of schizophrenia patients (R > 0, P < .05). In schizophrenia patients treated with olanzapine, the higher the olanzapine blood concentration in patients, the better the clinical treatment effect. Accordingly, the clinical can develop individualized medication regimens based on the results of blood concentration testing in the body under the premise of ensuring safety, aiming to ensure maximum efficacy. |
format | Online Article Text |
id | pubmed-9997772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-99977722023-03-10 Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients Yuan, Mei Yuan, Bo-Zhi Wu, Jiang Medicine (Baltimore) 6500 To analyze the relationship between olanzapine blood concentration and clinical efficacy in schizophrenia patients, which has been expected to provide a scientific reference basis for improving the treatment effect of olanzapine in schizophrenia patients. Four hundred eighty-six psychiatric inpatients were randomly selected from October 31, 2019, to October 31, 2020, and all enrolled patients were given olanzapine treatment, and the treatment effect of schizophrenia patients was assessed according to the Positive and Negative Symptom Scale subtraction rate, and divided into treatment effective and ineffective groups at 1, 2, and 3 weeks of treatment, respectively. The olanzapine blood concentration in the body was monitored at 1, 2, and 3 weeks of treatment, and the relationship between olanzapine blood concentration and treatment effect at different time points was analyzed. Patients in the ineffective group had lower olanzapine blood concentrations than the effective group in treatment 1, 2, and 3 weeks and lower Positive and Negative Symptom Scale score reduction rates than the effective group (P < .05); the differences in other baseline information between the groups were not statistically significant (P > .05). Logistic regression analysis showed that olanzapine blood concentration at different times of treatment was related to the treatment effect (odds ratio > 1, P < .05); the results of the bivariate Spearman linear correlation test showed that olanzapine blood concentration at different times of treatment was positively related to the treatment effect of schizophrenia patients (R > 0, P < .05). In schizophrenia patients treated with olanzapine, the higher the olanzapine blood concentration in patients, the better the clinical treatment effect. Accordingly, the clinical can develop individualized medication regimens based on the results of blood concentration testing in the body under the premise of ensuring safety, aiming to ensure maximum efficacy. Lippincott Williams & Wilkins 2023-03-10 /pmc/articles/PMC9997772/ /pubmed/36897697 http://dx.doi.org/10.1097/MD.0000000000032912 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 6500 Yuan, Mei Yuan, Bo-Zhi Wu, Jiang Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients |
title | Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients |
title_full | Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients |
title_fullStr | Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients |
title_full_unstemmed | Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients |
title_short | Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients |
title_sort | analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients |
topic | 6500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997772/ https://www.ncbi.nlm.nih.gov/pubmed/36897697 http://dx.doi.org/10.1097/MD.0000000000032912 |
work_keys_str_mv | AT yuanmei analysisofthecorrelationbetweenclinicalefficacyandbloodconcentrationofolanzapineinschizophreniapatients AT yuanbozhi analysisofthecorrelationbetweenclinicalefficacyandbloodconcentrationofolanzapineinschizophreniapatients AT wujiang analysisofthecorrelationbetweenclinicalefficacyandbloodconcentrationofolanzapineinschizophreniapatients |